Mycophenolate Mofetil Accord (Mycophenolate Mofetil)

• Mycophenolate Mofetil is used as an immunosuppressive agent to control immune‑mediated rejection and autoimmunity.
• Kidney transplant: helps maintain graft function and reduces acute rejection episodes.
• Heart transplant: lowers risk of organ rejection and improves long‑term survival.
• Liver transplant: prevents immune‑driven graft injury and supports transplant success.
• Lupus nephritis: reduces renal inflammation and slows disease progression.
• Pancreas transplant: decreases incidence of rejection and preserves endocrine function.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the enzyme responsible for de novo synthesis of guanosine nucleotides in lymphocytes. By depleting guanosine pools, it blocks proliferation of T and B cells, which rely heavily on this pathway, thereby dampening the adaptive immune response without markedly affecting other cell types.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Abdominal pain
• Vomiting
• Upper respiratory tract infections

Serious or Rare Side Effects

• Bone marrow suppression leading to anemia, leukopenia or thrombocytopenia
• Severe opportunistic infections, including fungal and viral pathogens
• Progressive multifocal leukoencephalopathy (PML)
• Hepatic toxicity with elevated transaminases
• Teratogenic effects causing fetal malformations
• Malignancies such as post‑transplant lymphoproliferative disorder

• When prescribing Mycophenolate Mofetil, clinicians should observe several safety measures.
• Monitor blood counts: perform regular complete blood count to detect marrow suppression.
• Assess renal function: check serum creatinine and eGFR periodically.
• Evaluate liver enzymes: monitor hepatic transaminases for potential toxicity.
• Avoid use in pregnancy: drug is contraindicated due to high teratogenic risk.
• Limit live vaccines: patients should not receive live attenuated vaccines while on therapy.
• Store at below 25°C: keep in original container, protect from moisture and heat.

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression.
• Rifampin: induces metabolism, markedly reducing drug levels.
• Antacids containing aluminum or magnesium: decrease oral absorption.
• Cholestyramine or other bile‑acid sequestrants: bind drug and lower bioavailability.
• Live vaccines: increase risk of severe infection.

Moderate Interactions (Monitor Closely)

• Cyclosporine or tacrolimus: may increase mycophenolate exposure; dose adjustment may be required.
• ACE inhibitors or ARBs: combined use may affect renal function; monitor creatinine.
• NSAIDs: can worsen renal impairment; check kidney parameters.